STL Volume 27 Number 1
4 POSTS 0 COMMENTSPurchase PDF for $2.79
Clascoterone 1% cream represents a novel and promising therapeutic agent in the management of acne vulgaris for individuals ≥12 years of age. Notably, this topical agent was not observed to have significant systemic effects seen with systemic anti-androgenic agents.
Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety...
Currently, JAK inhibitors are only FDA approved for dermatologic, rheumatologic, and hematologic conditions. Recent studies show the utility of JAK inhibitors in treating atopic dermatitis, psoriasis, psoriatic arthritis, vitiligo, and alopecia areata.
Drug update covering: Adalimumab-adbm for SC use - Cyltezo®, Tralokinumab for SC use - Adtralza® (in Canada), Tralokinumab-ldrm for SC use - Adbry™ (in US), Melanoma vaccine for IV use - BNT111, Adalimumab-aqvh for SC use - Yusimry™, and more...
This index covers all articles published in Skin Therapy Letter Dermatology Edition articles in 2021. Articles are indexed by drug names, trade names and disease terms. Bold entries refer to major references.